Fig. 6: KPNB1 inhibition-induced autophagy restrains the cytotoxicity of TRAIL.
From: Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells
a U87 and U251 cells expressing shKPNB1s or treated with IPZ (16 μM) for 24 h were subjected to western blot. b, c U251 cells expressing shATG5, shp62 or shLC3B were treated with IPZ (16 μM) or IVM (16 μM) for 24 h and further with TRAIL (100 ng/ml) for 6 h (western blot) or 24 h (flow cytometry), then subjected to flow cytometry (b) and western blot c. Results represent mean ± SD from three independent experiments. d, e U251 cells were pretreated with CQ (40 μM) or Baf-A1 (5 nM) along with IPZ (16 μM) or IVM (16 μM) for 24 h and further with TRAIL as in b, then subjected to flow cytometry (d) and western blot (e). Results represent mean ± SD from three independent experiments. GAPDH was used as the loading control. *P < 0.05
